Core Viewpoint - *ST Changyao has been found to have committed financial fraud for three consecutive years, leading to potential penalties and the risk of forced delisting from the stock market [1][2] Group 1: Financial Misconduct - *ST Changyao received an administrative penalty notice from the China Securities Regulatory Commission for false reporting in annual reports for 2021, 2022, and 2023 [1] - The company inflated its operating revenue by CNY 215 million, CNY 284 million, and CNY 234 million for the years 2021, 2022, and 2023, respectively, which accounted for 9.12%, 17.57%, and 19.51% of the disclosed operating revenue for those years [2] - The total profit was inflated by CNY 56 million, CNY 63 million, and CNY 44 million for the same years, representing 35.62%, 88.23%, and 6.42% of the disclosed profit totals [2] Group 2: Penalties and Consequences - The total proposed penalties amount to CNY 41 million, with *ST Changyao facing a fine of CNY 10 million, and the former actual controller, Luo Ming, facing a fine of CNY 5 million [2] - Other executives may face fines ranging from CNY 1 million to CNY 3 million, with Luo Ming potentially facing a lifetime ban from the securities market and another executive facing a 10-year ban [2] - The company has indicated that its stock may be subject to forced delisting due to significant legal violations [2] Group 3: Business Operations - *ST Changyao's main business operations include pharmaceuticals and photovoltaic products [1]

本文是我的新书《财报真相》节选，京东当当热销，上架2周已加印。 我从一个故事讲起。 2016年9月底，几位新三板董秘财总来上海开会，相聚甚欢。 老友沈总和另外一位董秘聊起最近他在新三板买的一只股票亨某股份，价格不但跌破净资产，还跌破现金价值。 闻言我耳朵立了起来：这不是格雷厄姆倡导的net-net投资法标的吗？ 我随手打开手机看了看数据。亨某股份是家做鞋的公司，规模在新三板上算大的，销售额有几个亿，利润有千万，不到一年前定增发行价还有 8块多，现在股价跌到2块多。 既然沈总重仓，肯定做过研究。我顺手就下了单买了一些。后来几天有朋友问新三板有啥好标的，我随口就推荐了亨某股份。过了几天是国庆 假期，我想起亨某股份，就找来材料看。 一看发现有问题，亨某股份业绩近几年大幅下滑，但是存货和应收账款却未收缩，总额还在上升。存货和应收账款减值计提不充分，这是典型 财务造假信号。 另外，我还发现其账上有几亿元的货币资金。股价跌成这样，如果公司没问题，老板理性做法是分红再增持，不做一定是哪里有问题。 我搜索了一下发现亨某股份负面新闻很多，员工上街讨薪、政府出面纾困等都预示着亨某股份处于困境之中，绝不是股价错杀的问题。 我立即拿 ...

郭晨凯 制图 ◎记者 胡嘉树 2025年，中国资本市场"零容忍"监管态势持续升级，针对一批连续多年、系统性财务造假的上市公司， 中国证监会等监管部门严厉打击、严肃惩处，形成应退尽退、及时出清的常态化退市格局。 12月26日，证监会对上市公司长江医药控股股份有限公司（简称"*ST长药"）定期报告等财务数据存在 虚假记载作出行政处罚事先告知。经查，*ST长药连续三年虚增收入和利润，违反证券法律法规。*ST 长药涉嫌触及重大违法强制退市情形，深交所将依法启动退市程序。这是2025年监管重拳出击严重财务 造假案的最新一例。 据上海证券报记者统计，今年以来，已有12家上市公司触及重大违法强制退市情形，相继终止上市或进 入退市程序，部分公司触发重大违法强制退市后，股价一路下跌最终以面值退市等交易类强制退市情形 率先退出市场。此外，还有40余家上市公司因财务造假、信息披露违规等事项，在收到证监会《行政处 罚事先告知书》后，被实施其他风险警示（ST）。 从违规类型来看，触及重大违法强制退市情形的公司多涉及系统性财务造假、欺诈发行等严重违法违规 行为；而被实施ST的公司，违规事项主要集中在年报虚假记载、控股股东非经营性资金占用 ...

Core Viewpoint - The stock price of ST Yuanzhi (002689.SZ) has dropped by 28.5% from November 29 to December 26 due to the announcement of an administrative penalty for financial misconduct involving inflated revenue recognition through forged acceptance certificates [1][2]. Group 1: Financial Misconduct Details - From 2019 to June 2022, ST Yuanzhi inflated its operating revenue by a total of 336 million yuan and inflated its total profit by approximately 93.26 million yuan [2][3]. - The company recognized revenue prematurely for non-ownership elevator products without obtaining necessary inspection reports, leading to inflated revenues of 123 million yuan, 66.22 million yuan, and 138 million yuan for the years 2019, 2020, and 2021, respectively [3][4]. - In the first half of 2022, the company reported a reduction in revenue of 16.11 million yuan and a reduction in profit of 23.45 million yuan [3]. Group 2: Penalties and Regulatory Response - The Liaoning Securities Regulatory Bureau imposed a warning and a fine of 6 million yuan on ST Yuanzhi, while the involved seven key executives were fined a total of 15 million yuan [5][6]. - The penalties reflect a regulatory trend of holding individuals accountable for financial misconduct, emphasizing a "zero tolerance" approach to financial fraud [8][10]. - The penalties for ST Yuanzhi are seen as part of a broader regulatory trend where fines for companies and individuals have significantly increased, with a focus on creating a multi-faceted accountability mechanism [9][10].

Group 1 - The China Securities Regulatory Commission (CSRC) has issued a prior administrative penalty notice against Changjiang Pharmaceutical Holdings Co., Ltd. (*ST Changyao*) for suspected false records in periodic reports and financial data [1] - *ST Changyao has inflated revenue and profits for three consecutive years, violating securities laws and regulations [1] - The CSRC plans to impose a fine of 10 million yuan on the company and a total of 31 million yuan on 14 responsible individuals, with the former general manager, Luo Ming, facing a lifetime ban from the securities market [1] Group 2 - *ST Changyao is potentially the 15th company this year facing mandatory delisting due to financial fraud, marking a record high for the number of companies reaching this threshold in a single year [1] - The increase in companies facing mandatory delisting is attributed to new regulations adjusting the delisting standards for financial fraud, as well as a strict regulatory stance against such practices [1] - The combination of administrative penalties, market bans, criminal referrals, delisting execution, and accountability for intermediaries is seen as a benchmark for the rule of law in the capital market, creating a closed-loop system for accountability [2]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has imposed severe penalties on Changjiang Pharmaceutical Holdings Co., Ltd. (*ST Changyao) for serious financial fraud, including inflated revenue and profits over three consecutive years, leading to potential delisting due to major violations [1][2]. Group 1: Financial Misconduct - *ST Changyao has been found to have inflated revenue by CNY 215 million, CNY 284 million, and CNY 234 million for the years 2021, 2022, and 2023 respectively, representing 9.12%, 17.57%, and 19.51% of the reported revenue for those years [2]. - The company also inflated total profits by CNY 56.4 million, CNY 63.4 million, and CNY 43.7 million for the same years, accounting for 35.62%, 88.23%, and 6.42% of the reported profits [2]. - In 2022, the company failed to reasonably recognize losses related to a project, resulting in an additional profit inflation of CNY 4.55 million, which was 6.34% of the reported profit for that year [2]. Group 2: Regulatory Actions and Consequences - The CSRC plans to impose a fine of CNY 10 million on *ST Changyao and a total of CNY 31 million on 14 responsible individuals, summing up to a total penalty of CNY 41 million [1]. - The former general manager of *ST Changyao, Luo Ming, will face a lifetime ban from the securities market [1]. - The Shenzhen Stock Exchange will initiate delisting procedures due to the company's serious violations [1][2]. Group 3: Financial Health and Future Risks - As of the end of 2024, the company's net assets attributable to shareholders are projected to be -CNY 433 million, and by the end of the third quarter of 2025, they are expected to be -CNY 643 million [3]. - If the audited net assets for the end of 2025 are negative, the company will face financial delisting risks [3]. - The CSRC is also investigating the auditing firms involved with *ST Changyao, which has had the same auditing firm for five consecutive years, raising concerns about compliance and oversight [3].

Core Viewpoint - ST Changyuan is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, which raises concerns about its operational and stock price impacts [1] Group 1: Regulatory Investigation - On December 26, 2025, ST Changyuan received a notice from the CSRC regarding an investigation due to suspected information disclosure violations [1] - The company stated that its production and operational activities are currently normal and it will cooperate with the investigation while adhering to disclosure obligations [1] - The specific reasons for the alleged violations have not yet been disclosed, leading to market speculation about potential impacts on the company's operations and stock price [1] Group 2: Corporate Governance Issues - On December 23, 2025, ST Changyuan's largest shareholder, Zhuhai Gree Financial Investment Management Co., proposed a temporary shareholders' meeting to replace the chairman, Qiao Wenjian, who has been detained for suspected job-related violations [1] - Qiao Wenjian has held various positions within the company since June 2022, including president and chairman, and was appointed chairman only three months prior to his detention [1] Group 3: Financial Performance and Legal Challenges - ST Changyuan has faced significant financial difficulties, including losses and high debt levels, leading to its designation as a special treatment (ST) company due to financial fraud [2] - The company reported cumulative losses of 10.26 billion yuan and 9.78 billion yuan in 2021 and 2024, respectively, with total losses exceeding 11 billion yuan from 2020 to 2024 [3] - As of the third quarter of 2025, ST Changyuan achieved total revenue of 54.38 billion yuan, a year-on-year decrease of 1.34%, and reported a net loss of 3.28 billion yuan [3]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has taken serious action against Changjiang Pharmaceutical Holdings Co., Ltd. (*ST Changyao) for significant financial fraud, leading to potential delisting procedures by the Shenzhen Stock Exchange [2][5][10]. Group 1: Financial Fraud Details - *ST Changyao has been found to have inflated revenue and profits for three consecutive years, violating securities laws [5][8]. - The company is facing a proposed fine of 10 million CNY, with 14 responsible individuals facing a total fine of 31 million CNY, including a lifetime ban for the former general manager, Luo Ming [5][9]. - The inflated revenues reported were 215.32 million CNY, 283.74 million CNY, and 233.63 million CNY for the years 2021 to 2023, representing 9.12%, 17.57%, and 19.51% of the disclosed revenues respectively [8]. Group 2: Company Performance and Market Impact - As of September 30, 2025, *ST Changyao reported a net profit of -210 million CNY, a year-on-year decrease of 15.89% [11][12]. - The company's stock price has been in decline, closing at 1.47 CNY per share on December 26, 2023, with a total market value of only 515 million CNY [13]. - The company has also announced the suspension of operations for its wholly-owned subsidiary, Yiheng Technology, due to financial difficulties and ongoing losses [11][12].

Core Viewpoint - ST Changyuan is facing significant governance issues and financial distress, highlighted by the chairman's legal troubles and the company's declining performance, which raises concerns about its future direction and potential recovery [6][12][14]. Group 1: Governance Issues - On December 26, 2025, ST Changyuan received a notice from the China Securities Regulatory Commission regarding an investigation into alleged information disclosure violations [1]. - The chairman, Qiao Wenjian, has been detained since November 24, 2025, due to suspected job-related violations, leading to a governance vacuum as he has missed multiple board meetings [6][8]. - Major shareholder, Zhuhai Gree Financial Investment Management Co., proposed to replace Qiao and nominated Yang Tao as a new non-independent director, indicating a push for governance restructuring [3][10]. Group 2: Financial Performance - ST Changyuan has reported a continuous decline in financial performance, with a revenue of 54.38 billion yuan in Q3 2025, down 1.34% year-on-year, and a net profit of -3.28 billion yuan, a staggering drop of 567.01% [12][13]. - The company has experienced a significant drop in net profits over the years, with figures of 6.74 billion yuan in 2022, 0.88 billion yuan in 2023, and a projected -9.78 billion yuan in 2024, marking a 1243.44% decline [13]. - The company's debt situation is concerning, with total external guarantees amounting to 62.26 billion yuan, which is 152.38% of its latest audited net assets [14]. Group 3: Market Position and Strategy - ST Changyuan's business segments, primarily in smart grid equipment and consumer electronics, face intense competition, and the company needs to enhance its market position in the energy sector through differentiated solutions [13]. - The company has been labeled as a "ST" stock due to internal control failures, leading to a significant drop in share price from a peak of 28.47 yuan to around 3.50 yuan, reflecting a nearly 90% decline in market value [14].

又一家上市公司因财务造假走向退市终局。*ST长药因连续三年虚构收入、利润，被证监会重罚，并启 动强制退市程序，成为年内第15家触及重大违法退市红线的公司，数量创历史新高。 监管红线非常明确：财务造假行为持续满三年，就会触及重大违法强制退市。*ST长药正是撞上这 条"高压线"——2021至2023年，其子公司伪造单据虚增收入7.33亿元、利润1.68亿元。 与此同时，监管探照灯也照向中介机构，正核查其是否履职尽责，旨在彻底斩断造假生态链。 *ST长药从立案到下发告知书仅用一个月，监管效率大幅提升。这一切都传递出清晰信号：退市"出 口"正在畅通，财务造假此路不通；任何挑战底线者，都将被坚决清出市场。 （文章来源：21世纪经济报道） 处罚不仅针对公司，更重拳追责到人。14名责任人员被重罚，主导造假的原总经理被终身市场禁入。证 监会对犯罪线索"应移尽移"，行政、民事、刑事"三罚联动"的监管格局已经形成。 ...